News

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Dr. Olivier Elemento serves as Principal Investigator on SAMBAI (Societal, Ancestry and Molecular Biology Analyses of Inequalities), a National Cancer Institute-funded project running from 2024-2026 that aims to understand why cancer outcomes differ across populations.

This...

Dr. Olivier Elemento and colleagues have published two significant papers advancing the application of artificial intelligence in medicine.

"The use of artificial intelligence for cancer therapeutic decision-making" was published in NEJM AI (2025), exploring how AI can support oncologists in making treatment decisions.

"Artificial intelligence in hematology" was published in Blood (2025), reviewing the emerging role of AI technologies in the diagnosis and treatment...

Research led by Weill Cornell Medicine and the New York Genome Center has illuminated how bladder cancer originates and progresses. Dr. Olivier Elemento collaborated with Dr. Bishoy Faltas on this investigation into the genetic mechanisms underlying the disease.

The study used advanced genomic techniques to uncover key mutations and DNA structural changes that drive bladder cancer development, offering new insights that could lead to improved diagnostic and therapeutic...

Request an interview

To request an interview with Director Olivier Elemento, Ph.D., or any other member of the Elemento Lab, please contact the Weill Cornell Medicine Department of External Affairs Press Room

Weill Cornell Medicine Elemento Lab 413 E 69th St., Room 1404 New York, NY 10021 Phone: (646) 962-7604